Related references
Note: Only part of the references are listed.Functional star polymers as reagents for efficient nucleic acids delivery into HT-1080 cells
Agnieszka Fus-Kujawa et al.
INTERNATIONAL JOURNAL OF POLYMERIC MATERIALS AND POLYMERIC BIOMATERIALS (2021)
Amelioration of osteogenesis in iPSC-derived mesenchymal stem cells from osteogenesis imperfecta patients by endoplasmic reticulum stress inhibitor
Thitinat Duangchan et al.
LIFE SCIENCES (2021)
Targeting cellular stress in vitro improves osteoblast homeostasis, matrix collagen content and mineralization in two murine models of osteogenesis imperfecta
Nadia Garibaldi et al.
MATRIX BIOLOGY (2021)
Potential of Induced Pluripotent Stem Cells for Use in Gene Therapy: History, Molecular Bases, and Medical Perspectives
Agnieszka Fus-Kujawa et al.
BIOMOLECULES (2021)
Restoration of Osteogenesis by CRISPR/Cas9 Genome Editing of the Mutated COL1A1 Gene in Osteogenesis Imperfecta
Hyerin Jung et al.
JOURNAL OF CLINICAL MEDICINE (2021)
Denosumab or romosozumab therapy and risk of cardiovascular events in patients with primary osteoporosis: Systematic review and meta- analysis
Fang Lv et al.
BONE (2020)
Intravenous bisphosphonate therapy in children with spinal muscular atrophy
N. Nasomyont et al.
OSTEOPOROSIS INTERNATIONAL (2020)
Osteogenesis imperfecta: an update on clinical features and therapies
Ronit Marom et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2020)
Effects of prior osteoporosis treatment on early treatment response of romosozumab in patients with postmenopausal osteoporosis
Kosuke Ebina et al.
BONE (2020)
Induced Pluripotent Stem Cells: Reprogramming Platforms and Applications in Cell Replacement Therapy
Akram Al Abbar et al.
BIORESEARCH OPEN ACCESS (2020)
Generation of a heterozygous COL1A1 (c.3969_3970insT) osteogenesis imperfecta mutation human iPSC line, MCRIi001-A-1, using CRISPR/Cas9 editing
Hani Hosseini Far et al.
STEM CELL RESEARCH (2019)
Cellular stress due to impairment of collagen prolyl hydroxylation complex is rescued by the chaperone 4-phenylbutyrate
Roberta Besio et al.
DISEASE MODELS & MECHANISMS (2019)
The use of simultaneous reprogramming and gene correction to generate an osteogenesis imperfecta patient COL1A1 c. 3936 G > T iPSC line and an isogenic control iPSC line
Sara Howden et al.
STEM CELL RESEARCH (2019)
The Application of Induced Pluripotent Stem Cells in Pathogenesis Study and Gene Therapy for Vascular Disorders: Current Progress and Future Challenges
Guang-Yin Peng et al.
STEM CELLS INTERNATIONAL (2019)
Nosology and classification of genetic skeletal disorders: 2019 revision
Geert R. Mortier et al.
AMERICAN JOURNAL OF MEDICAL GENETICS PART A (2019)
Generation of a patient-specific induced pluripotent stem cell line, KSCBi006-A, for osteogenesis imperfecta type I with the COL1A1, c.3162delT mutation
Bo-Young Kim et al.
STEM CELL RESEARCH (2019)
Current concepts in osteogenesis imperfecta: bone structure, biomechanics and medical management
W. H. Nijhuis et al.
JOURNAL OF CHILDRENS ORTHOPAEDICS (2019)
Treatment of autosomal dominant hearing loss by in vivo delivery of genome editing agents
Xue Gao et al.
NATURE (2018)
4-PBA ameliorates cellular homeostasis in fibroblasts from osteogenesis imperfecta patients by enhancing autophagy and stimulating protein secretion
Roberta Besio et al.
BIOCHIMICA ET BIOPHYSICA ACTA-MOLECULAR BASIS OF DISEASE (2018)
Crispr-Cas9 engineered osteogenesis imperfecta type V leads to severe skeletal deformities and perinatal lethality in mice
Frank Rauch et al.
BONE (2018)
Skeletal Response to Soluble Activin Receptor Type IIB in Mouse Models of Osteogenesis Imperfecta
Youngjae Jeong et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2018)
Osteogenesis imperfecta and therapeutics
Roy Morello
MATRIX BIOLOGY (2018)
Systematic review of the effect of denosumab on children with osteogenesis imperfecta showed inconsistent findings
Guowei Li et al.
ACTA PAEDIATRICA (2018)
Genome Editing Techniques and Their Therapeutic Applications
M. P. Calos
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
The chaperone activity of 4PBA ameliorates the skeletal phenotype of Chihuahua, a zebrafish model for dominant osteogenesis imperfecta
Roberta Gioia et al.
HUMAN MOLECULAR GENETICS (2017)
BPS804 Anti-Sclerostin Antibody in Adults With Moderate Osteogenesis Imperfecta: Results of a Randomized Phase 2a Trial
Francis H. Glorieux et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2017)
Low bone mineral density and fractures are highly prevalent in pediatric patients with spinal muscular atrophy regardless of disease severity
Halley M. Wasserman et al.
NEUROMUSCULAR DISORDERS (2017)
Romosozumab or Alendronate for Fracture Prevention in Women with Osteoporosis
Kenneth G. Saag et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
The combination of stem cells and tissue engineering: an advanced strategy for blood vessels regeneration and vascular disease treatment
Ying Wang et al.
STEM CELL RESEARCH & THERAPY (2017)
Efficacy of teriparatide vs neridronate in adults with osteogenesis imperfecta type I: a prospective randomized international clinical study
Paolo Tranquilli Leali et al.
CLINICAL CASES IN MINERAL AND BONE METABOLISM (2017)
Phenotypic Variability in Patients with Osteogenesis Imperfecta Caused by BMP1 Mutations
Rebecca C. Pollitt et al.
AMERICAN JOURNAL OF MEDICAL GENETICS PART A (2016)
AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY CLINICAL PRACTICE GUIDELINES FOR THE DIAGNOSIS AND TREATMENT OF POSTMENOPAUSAL OSTEOPOROSIS-2016 EXECUTIVE SUMMARY
Pauline M. Camacho et al.
ENDOCRINE PRACTICE (2016)
Stem cells and bone diseases: New tools, new perspective
Mara Riminucci et al.
BONE (2015)
Fresolimumab treatment decreases biomarkers and improves clinical symptoms in systemic sclerosis patients
Lisa M. Rice et al.
JOURNAL OF CLINICAL INVESTIGATION (2015)
Allele-specific Col1a1 silencing reduces mutant collagen in fibroblasts from Brtl mouse, a model for classical osteogenesis imperfecta
Julie Rousseau et al.
EUROPEAN JOURNAL OF HUMAN GENETICS (2014)
Evaluation of teriparatide treatment in adults with osteogenesis imperfecta
Eric S. Orwoll et al.
JOURNAL OF CLINICAL INVESTIGATION (2014)
Excessive transforming growth factor-β signaling is a common mechanism in osteogenesis imperfecta
Ingo Grafel et al.
NATURE MEDICINE (2014)
Phase I Study of GC1008 (Fresolimumab): A Human Anti-Transforming Growth Factor-Beta (TGFβ) Monoclonal Antibody in Patients with Advanced Malignant Melanoma or Renal Cell Carcinoma
John C. Morris et al.
PLOS ONE (2014)
Potential of Human Fetal Chorionic Stem Cells for the Treatment of Osteogenesis Imperfecta
Gemma N. Jones et al.
STEM CELLS AND DEVELOPMENT (2014)
Pre- and Postnatal Transplantation of Fetal Mesenchymal Stem Cells in Osteogenesis Imperfecta: A Two-Center Experience
Cecilia Gotherstrom et al.
STEM CELLS TRANSLATIONAL MEDICINE (2014)
A Comparative View on Human Somatic Cell Sources for iPSC Generation
Stefanie Raab et al.
STEM CELLS INTERNATIONAL (2014)
Delivery of reprogramming factors into fibroblasts for generation of non-genetic induced pluripotent stem cells using a cationic bolaamphiphile as a non-viral vector
Majad Khan et al.
BIOMATERIALS (2013)
Osteogenesis imperfecta type V: marked phenotypic variability despite the presence of the IFITM5 c.-14C>T mutation in all patients
Frank Rauch et al.
JOURNAL OF MEDICAL GENETICS (2013)
Mutations in WNT1 are a cause of osteogenesis imperfecta
Somayyeh Fahiminiya et al.
JOURNAL OF MEDICAL GENETICS (2013)
Absence of FKBP10 in recessive type XI osteogenesis imperfecta leads to diminished collagen cross-linking and reduced collagen deposition in extracellular matrix
Aileen M. Barnes et al.
HUMAN MUTATION (2012)
Normal Collagen and Bone Production by Gene-targeted Human Osteogenesis Imperfecta iPSCs
David R. Deyle et al.
MOLECULAR THERAPY (2012)
Mutations in SERPINF1 Cause Osteogenesis Imperfecta Type VI
Erica P. Homan et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2011)
New perspectives on osteogenesis imperfecta
Antonella Forlino et al.
NATURE REVIEWS ENDOCRINOLOGY (2011)
Identification of a Frameshift Mutation in Osterix in a Patient with Recessive Osteogenesis Imperfecta
Pablo Lapunzina et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2010)
Homozygosity for a Missense Mutation in SERPINH1, which Encodes the Collagen Chaperone Protein HSP47, Results in Severe Recessive Osteogenesis Imperfecta
Helena E. Christiansen et al.
AMERICAN JOURNAL OF HUMAN GENETICS (2010)
Risedronate Reduces Intracortical Porosity in Women With Osteoporosis
Babul Borah et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2010)
Bone remodelling: its local regulation and the emergence of bone fragility
T. John Martin et al.
BEST PRACTICE & RESEARCH CLINICAL ENDOCRINOLOGY & METABOLISM (2008)
CRTAP and LEPRE1 Mutations in Recessive Osteogenesis Imperfecta
Dustin Baldridge et al.
HUMAN MUTATION (2008)
Brief report: Deficiency of cartilage-associated protein in recessive lethal osteogenesis imperfecta
Aileen M. Barnes et al.
NEW ENGLAND JOURNAL OF MEDICINE (2006)
CRTAP is required for prolyl 3-hydroxylation and mutations cause recessive osteogenesis imperfecta
Roy Morello et al.
CELL (2006)
Intravenous bisphosphonate therapy increases radial width in adults with osteogenesis imperfecta
D Gatti et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2005)
Bone neoplasms in F344 rats given teriparatide [rhPTH(1-34)] are dependent on duration of treatment and dose
JL Vahle et al.
TOXICOLOGIC PATHOLOGY (2004)
Positive linear growth and bone responses to growth hormone treatment in children with types III and IV osteogenesis imperfecta: High predictive value of the carboxyterminal propeptide of type I procollagen
JC Marini et al.
JOURNAL OF BONE AND MINERAL RESEARCH (2003)
Share Paper
